Lobe Sciences to Showcase Low-Dose Psilocin Data at Summit

Lobe Sciences Ltd. will present at the 9th Neuropsychiatric Drug Development Summit in Boston. Dr. Frederick D. Sancilio, the company's CEO, will discuss Conjugated Psilocin™ (L-130) on September 16. This event occurs from September 15-17, 2026.

The presentation, titled "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm," details Phase 1a results. These results suggest consistent oral bioavailability and minimal hallucinogenic effects at low doses. It highlights L-130's potential for outpatient use instead of supervised administration common in psychedelic treatments.

Lobe will also exhibit at the summit alongside major pharmaceutical companies. This three-day event focuses on drug development for neuropsychiatric conditions.